

Table S1 The relationship between PET/CT parameters and clinical data

Participant data	No. of participants (n=184)	TMTV			TLG		
		Low (n=103)	High (n=81)	P value*	Low (n=101)	High (n=83)	P value*
Gender, F/M	85/99	53/50	32/49	0.136	52/49	33/50	0.138
Age, ≤60/>60	102/82	52/51	49/32	0.183	49/52	52/31	0.074
LDH level, normal/elevated	96/88	67/36	29/52	<0.001	69/32	27/56	<0.001
B symptoms, no/yes	108/76	69/34	39/42	0.011	70/31	38/45	0.002
Bone marrow involved, no/yes	127/57	85/18	42/39	<0.001	81/20	46/37	<0.001
Extranodal involvement, 0–1/≥2	88/96	68/35	20/61	<0.001	65/36	23/60	<0.001
ECOG PS, 0–1/≥2	118/66	82/21	36/45	<0.001	81/20	37/46	<0.001
Ann Arbor stage, I–II/III–IV	59/125	52/51	7/74	<0.001	50/51	9/74	<0.001
NCCN-IPI, 0–3/≥4	82/102	65/38	17/64	<0.001	64/37	18/65	<0.001
Bulky disease, no/yes	126/58	79/24	47/34	0.010	79/22	47/36	0.002
Cell of origin subtypes, GCB/ non-GCB	93/91	51/52	42/39	0.768	46/55	47/36	0.142

*, P<0.05. PET, positron emission tomography; CT, computed tomography; TMTV, total metabolic tumor volume; TLG, total lesion glycolysis; LDH, lactic acid dehydrogenase; ECOG PS, Eastern Cooperative Oncology Group performance status; NCCN-IPI, National Comprehensive Cancer Network International Prognostic Index; GCB, germinal center B-cell.

Table S2 The revised risk model in predicting PFS and OS of patients in different age subgroups

Age subgroup	Risk stratification	No. of participants	3-year progression-free survival				3-year overall survival			
			Number of events	Survival (%)	χ^2 (P value*)		Number of events	Survival (%)	χ^2 (P value*)	
≤60 years old	Low	21	2	90.5	1.284 (0.257)	23.961 (<0.001)	1	95.2	0.912 (0.340)	9.931 (0.019)
	Low-intermediate	37	8	78.4			6	83.8		
	High-intermediate	24	5	79.2	8.333 (0.004)		5	79.2	2.134 (0.144)	
	High	19	13	31.6			8	57.9		
>60 years old	Low	8	1	87.5	1.629 (0.202)	19.133 (<0.001)	1	87.5	0.637 (0.425)	21.370 (<0.001)
	Low-intermediate	28	14	50.0			11	60.7		
	High-intermediate	36	24	33.3	8.551 (0.003)		21	41.7	10.819 (0.001)	
	High	11	9	18.2			9	18.2		

*, P<0.05. PFS, progression-free survival; OS, overall survival.